NCT07812623 A Twelve-Week Pilot Study Evaluating the Usability and Preliminary Effects of SugarVita 2.0 in Adults With Type 2 Diabetes
| NCT ID | NCT07812623 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Maxima Medical Center |
| Condition | Diabetes Mellitus |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2026-08-05 |
| Primary Completion | 2027-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2026-08-05 with a primary completion date of 2027-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Diabetes self-management education is essential for achieving optimal glycemic control, but conventional education does not meet the needs of all patients. SugarVita 2.0 is a serious digital game designed to improve diabetes self-management through interactive gameplay and a semi-personalized glucose simulator. This multicenter, single-arm, 12-week pilot study will evaluate the usability of SugarVita 2.0 and its effects on diabetes self-management, self-confidence, diabetes-related distress, diabetes knowledge, HbA1c, and user engagement in adults with type 2 diabetes.
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 years or older * Diagnosis of type 2 diabetes mellitus (T2DM) * Written informed consent obtained before any study procedures * HbA1c \>55 mmol/mol prior to study participation * For participants with T2DM only: BMI \>25 kg/m² * Sufficient command of the Dutch language to complete study questionnaires Exclusion Criteria: * Pregnancy or breastfeeding * Active malignancy, except adequately treated basal cell carcinoma or squamous cell carcinoma of the skin
Contact & Investigator
Pleun Wouters - van Poppel, MSc
PRINCIPAL INVESTIGATOR
Maxima Medical Center
Frequently Asked Questions
Who can join the NCT07812623 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Diabetes Mellitus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07812623 currently recruiting?
Yes, NCT07812623 is actively recruiting participants. Contact the research team at pleun.van.poppel@mmc.nl for enrollment information.
Where is the NCT07812623 trial being conducted?
This trial is being conducted at Eindhoven, Netherlands.
Who is sponsoring the NCT07812623 clinical trial?
NCT07812623 is sponsored by Maxima Medical Center. The principal investigator is Pleun Wouters - van Poppel, MSc at Maxima Medical Center. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.